Trial Data Available on Govorestat for Galactosemia
https://unsplash.com/photos/P7MkoYvSnLI

Trial Data Available on Govorestat for Galactosemia

In a news release on the company’s website, biopharmaceutical company Applied Therapeutics, Inc. shared that positive data was available from the Phase 3 ACTION-Galactosemia Kids trial. Within the trial, researchers…

Continue Reading Trial Data Available on Govorestat for Galactosemia
Rare Community Profiles: Creating a Caregiver-Centric Social Platform: An Interview with Comend’s Albert Wang and Flawnson Tong
source: shutterstock.com

Rare Community Profiles: Creating a Caregiver-Centric Social Platform: An Interview with Comend’s Albert Wang and Flawnson Tong

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: Creating a Caregiver-Centric Social Platform: An Interview with Comend’s Albert Wang and Flawnson Tong
April 28: Carteret Community College Holds Annual “Great Strides” Walk for Cystic Fibrosis
https://pixabay.com/en/people-autumn-walking-blur-fall-1132524/

April 28: Carteret Community College Holds Annual “Great Strides” Walk for Cystic Fibrosis

Each year, students at Carteret Community College in Morehead City, North Carolina participate in the “Great Strides” Walk for Cystic Fibrosis. “Great Strides” is the Cystic Fibrosis Foundation’s largest fundraising…

Continue Reading April 28: Carteret Community College Holds Annual “Great Strides” Walk for Cystic Fibrosis
Rare Community Profiles: Heart Attack at 27: How an HoFH Diagnosis Allowed Peter to Live a More Empowered Life
source: shutterstock.com

Rare Community Profiles: Heart Attack at 27: How an HoFH Diagnosis Allowed Peter to Live a More Empowered Life

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: Heart Attack at 27: How an HoFH Diagnosis Allowed Peter to Live a More Empowered Life
This Company Just Withdrew Two of Its Drug Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma
source: shutterstock.com

This Company Just Withdrew Two of Its Drug Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma

According to a story from BioPharma Dive, the drug company AbbVie has recently announced its decision to withdraw two different approvals for its cancer therapy Imbruvica. The approvals were withdrawn…

Continue Reading This Company Just Withdrew Two of Its Drug Approvals for Mantle Cell Lymphoma and Marginal Zone Lymphoma
Rare Community Profiles: Study Investigator Dr. Weyand Discusses the Trial Data that Led to ALTUVIIIO Approval for Hemophilia A
source: shutterstock.com

Rare Community Profiles: Study Investigator Dr. Weyand Discusses the Trial Data that Led to ALTUVIIIO Approval for Hemophilia A

Rare Community Profiles     Rare Community Profiles is a new Patient Worthy article series of long-form interviews featuring various stakeholders in the rare disease community, such as patients, their…

Continue Reading Rare Community Profiles: Study Investigator Dr. Weyand Discusses the Trial Data that Led to ALTUVIIIO Approval for Hemophilia A
Study of the Week: Niemann-Pick Disease Type C Biomarker Could Help Diagnose Congenital Disorders of Glycosylation
source: pixabay.com

Study of the Week: Niemann-Pick Disease Type C Biomarker Could Help Diagnose Congenital Disorders of Glycosylation

Welcome to Study of the Week from Patient Worthy. In this segment, we select a study we posted about from the previous week that we think is of particular interest…

Continue Reading Study of the Week: Niemann-Pick Disease Type C Biomarker Could Help Diagnose Congenital Disorders of Glycosylation